Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

IMPORTANCE: Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about the optimal TMB threshold that best discriminates improved outcomes of immune checkpoint inhibitor therapy among patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciuti, Biagio, Wang, Xinan, Alessi, Joao V., Rizvi, Hira, Mahadevan, Navin R., Li, Yvonne Y., Polio, Andrew, Lindsay, James, Umeton, Renato, Sinha, Rileen, Vokes, Natalie I., Recondo, Gonzalo, Lamberti, Giuseppe, Lawrence, Marissa, Vaz, Victor R., Leonardi, Giulia C., Plodkowski, Andrew J., Gupta, Hersh, Cherniack, Andrew D., Tolstorukov, Michael Y., Sharma, Bijaya, Felt, Kristen D., Gainor, Justin F., Ravi, Arvind, Getz, Gad, Schalper, Kurt A., Henick, Brian, Forde, Patrick, Anagnostou, Valsamo, Jänne, Pasi A., Van Allen, Eliezer M., Nishino, Mizuki, Sholl, Lynette M., Christiani, David C., Lin, Xihong, Rodig, Scott J., Hellmann, Matthew D., Awad, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204620/
https://www.ncbi.nlm.nih.gov/pubmed/35708671
http://dx.doi.org/10.1001/jamaoncol.2022.1981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204620/
https://www.ncbi.nlm.nih.gov/pubmed/35708671
http://dx.doi.org/10.1001/jamaoncol.2022.1981

Ejemplares similares